Herzogenrath, Germany
Herzogenrath, Germany

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.4-1 | Award Amount: 7.85M | Year: 2011

Large full-thickness skin defects resulting from burns, soft tissue trauma, congenital giant nevi, tumour resection, and disease leading to skin necrosis, represent a significant and common clinical problem worldwide. This problem is far from being solved. The main challenge encountered is that most autologous skin grafting techniques are based on transplanting split-thickness skin (the todays gold standard). Split-thickness skin contains all of the epidermis, but only remnants of the dermis. This lack of dermal tissue, frequently leads to significant scarring. Consequently, a true dermal substitute is required, which instantly exerts the cell-instructive properties of a neo-dermis. The partners of EuroSkinGraft can now offer 2 dermal substitutes, Novomaix and denovoDerm, plus the dermo-epidermal skin substitute denovoSkin. The development of all 3 substitutes was significantly supported by the FP6-program (EuroSTEC). The envisaged clinical studies are aiming strictly at a one-step surgical procedure (instead of the common two-step procedure, using Integra Artificial Skin).This is to be reached with the following protocol: Clinical application of Novomaix 1. Experimental arm 1: split-thickness skin on Novomaix applied on full-thickness wounds 2. Reference arm 1: split-thickness skin applied directly on the wound bed Clinical application of denovoDerm 1. Experimental arm 1: split-thickness skin on denovoDerm applied on full-thickness wounds 2. Reference arm 1: split-thickness skin applied directly on the wound bed Clinical application of denovoSkin 1. Experimental arm 1: denovoSkin applied on full-thickness wounds 2. Reference arm 1: split-thickness skin applied directly on the wound bed The strength of this project lies in: the high degree to which real regenerative medicine is translated into the clinic, the innovative and highly functional character of the 3 products to be tested, the central contribution of the 3 SMEs, and the excellence of the 3 clinics.


News Article | November 28, 2016
Site: www.newsmaker.com.au

In terms of revenue, the global AMIC market is projected to register a CAGR of 8.6% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights and forecasts. The global Autologous Matrix-Induced Chondrogenesis market value in 2016 is estimated to be US$ 96.11 Mn and this is expected to increase to US$ 186.4 Mn by the end of 2024. Autologous Matrix-Induced Chondrogenesis (AMIC) is a biological treatment method to repair articular cartilage damage. AMIC therapy is a step wise process. Micro fracture surgery is followed by application of a bi-layer collagen I/III membrane. It slows down cartilage degeneration with an intent to avoid or delay partial or total joint replacement (e.g. knee replacement) surgery. The indications for AMIC includes Grade III or IV chondral lesions with lesion size of about 2 cm­­2 to 8cm­­2. Growth of the global Autologous Matrix-Induced Chondrogenesis market is mainly driven by increasing demand for minimally invasive procedures, rising prevalence of bone and joint disorders and a surge in sports injuries. Another prominent growth driver is the faster uptake and access along with affordable pricing. However, lack of clinical data and lack of efficient reimbursement is expected to restrain growth of the market over the forecast period. The market is segmented based on material type and regions. Based on material type, the market is segmented into Hyaluronic Acid, Collagen, Polyethylene glycol (PEG), polylactic-co-glycolic acid (PGLA) and others. The PEG segment is expected to grow with a healthy CAGR over the forecast period, owing to its ability to be gelled into complex defects in situ using UV-light. The segment is expected to register a significant CAGR of 11.1 % during the forecast period. The Others segment, which includes PLLA, agarose-alginate, chitosan, poly (ester-ether) polydioxanone, etc. is anticipated to grow with a CAGR of 8.1%. Segments such as hyaluronic acid and collagen are expected to register a CAGR of 8.9% and 8.2% respectively over the forecast period. The PGLA segment is expected to witness a CAGR of 9.2% over the forecast period. This report assesses trends that drive growth of each segment on the global as well as regional levels and offers potential takeaways that could prove substantially useful to surgical products manufacturing companies that wish to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market. North America is anticipated to dominate the global Autologous Matrix-Induced Chondrogenesis (AMIC) market with maximum market share in 2016. North America is expected to account for more than 38% of the total Autologous Matrix-Induced Chondrogenesis (AMIC) market share in terms of value in 2016. Followed by North America, Europe is one of the established markets for AMIC. Europe contributes to around 34% of the total market share in 2016. Among emerging markets, Asia Pacific is estimated to exhibit the highest CAGR of 10.3% over the forecast period, due to higher adoption of AMIC procedures in the region. Some key players in the global Autologous Matrix-Induced Chondrogenesis (AMIC) market identified in the report include Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun Melsungen AG, BioTissue AG, CartiHeal, Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew plc, and Zimmer Biomet Holdings. Persistence Market Research has discussed individual strategies of these companies in terms of increasing focus on overcoming major hindrances through innovation and enhancing the distribution base. The report concludes with strategic recommendations for players already present in the market and new players planning to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market.


The global AMIC market is projected to register a CAGR of 8.6% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights and forecasts. The global Autologous Matrix-Induced Chondrogenesis market value in 2016 is estimated to be US$ 96.11 Mn. Growth of the global Autologous Matrix-Induced Chondrogenesis market is mainly driven by increasing demand for minimally invasive procedures, rising prevalence of bone and joint disorders and a surge in sports injuries. Another prominent growth driver is the faster uptake and access along with affordable pricing. However, lack of clinical data and lack of efficient reimbursement is expected to restrain growth of the market over the forecast period. The market is segmented based on material type and regions. Based on material type, the market is segmented into Hyaluronic Acid, Collagen, Polyethylene glycol (PEG), polylactic-co-glycolic acid (PGLA) and others. The PEG segment is expected to grow with a healthy CAGR over the forecast period, owing to its ability to be gelled into complex defects in situ using UV-light. The segment is expected to register a significant CAGR of 11.1 % during the forecast period. The others segment, which includes PLLA, agarose-alginate, chitosan, poly (ester-ether) polydioxanone, etc. is anticipated to grow with a CAGR of 8.1%. Segments such as hyaluronic acid and collagen are expected to register a CAGR of 8.9% and 8.2% respectively over the forecast period. The PGLA segment is expected to witness a CAGR of 9.2% over the forecast period. North America is anticipated to dominate the global Autologous Matrix-Induced Chondrogenesis (AMIC) market with maximum market share in 2016. North America is expected to account for more than 38% of the total Autologous Matrix-Induced Chondrogenesis (AMIC) market share in terms of value in 2016. Followed by North America, Europe is one of the established markets for AMIC. Europe contributes to around 34% of the total market share in 2016. Among emerging markets, Asia Pacific is estimated to exhibit the highest CAGR of 10.3% over the forecast period, due to higher adoption of AMIC procedures in the region. View and Download Report Table of Contents, Figures, and Tables@ http://www.persistencemarketresearch.com/market-research/autologous-matrixinduced-chondrogenesis-market/toc "Persistence Market Research has discussed individual strategies of these companies in terms of increasing focus on overcoming major hindrances through innovation and enhancing the distribution base. The report concludes with strategic recommendations for players already present in the market and new players planning to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market". Some key players in the global Autologous Matrix-Induced Chondrogenesis (AMIC) market identified in the report include Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun Melsungen AG, BioTissue AG, CartiHeal, Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew plc, and Zimmer Biomet Holdings. Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


PubMed | Uniklinik Aachen, Matricel GmbH, Jülich Research Center, University of Toronto and 3 more.
Type: | Journal: Brain research | Year: 2014

The formation of cystic cavitation following severe spinal cord injury (SCI) constitutes one of the major barriers to successful axonal regeneration and tissue repair. The development of bioengineered scaffolds that assist in the bridging of such lesion-induced gaps may contribute to the formulation of combination strategies aimed at promoting functional tissue repair. Our previous in vitro investigations have demonstrated the directed axon regeneration and glial migration supporting properties of microstructured collagen scaffold that had been engineered to possess mechanical properties similar to those of spinal cord tissues. Here, the effect of implanting the longitudinally orientated scaffold into unilateral resection injuries (2mm long) of the mid-cervical lateral funiculus of adult rats has been investigated using behavioural and correlative morphological techniques. The resection injuries caused an immediate and long lasting (up to 12 weeks post injury) deficit of food pellet retrieval by the ipsilateral forepaw. Implantation of the orientated collagen scaffold promoted a significant improvement in pellet retrieval by the ipsilateral forepaw at 6 weeks which continued to improve up to 12 weeks post injury. In contrast, implantation of a non-orientated gelatine scaffold did not result in significant functional improvement. Surprisingly, the improved motor performance was not correlated with the regeneration of lesioned axons through the implanted scaffold. This observation supports the notion that biomaterials may support functional recovery by mechanisms other than simple bridging of the lesion site, such as the local sprouting of injured, or even non-injured fibres.


Mertens M.E.,RWTH Aachen | Hermann A.,Matricel GmbH | Buhren A.,Matricel GmbH | Olde-Damink L.,Matricel GmbH | And 6 more authors.
Advanced Functional Materials | Year: 2014

Non-invasive imaging holds significant potential for implementation in tissue engineering. It can be used to monitor the localization and function of tissue-engineered implants, as well as their resorption and remodelling. Thus far, however, the vast majority of effort in this area of research have focused on the use of ultrasmall super-paramagnetic iron oxide (USPIO) nanoparticle-labeled cells, colonizing the scaffolds, to indirectly image the implant material. Reasoning that directly labeling scaffold materials might be more beneficial (enabling imaging also in the case of non-cellularized implants), more informative (enabling the non-invasive visualization and quantification of scaffold degradation), and easier to translate into the clinic (cell-free materials are less complex from a regulatory point-of-view), three different types of USPIO nanoparticles are prepared and incorporated both passively and actively (via chemical conjugation; during collagen crosslinking) into collagen-based scaffold materials. The amount of USPIO incorporated into the scaffolds is optimized, and correlated with MR signal intensity, showing that the labeled scaffolds are highly biocompatible, and that scaffold degradation can be visualized using MRI. This provides an initial proof-of-principle for the in vivo visualization of the scaffolds. Consequently, USPIO-labeled scaffold materials seem to be highly suitable for image-guided tissue engineering applications. Three-dimensional collagen-based scaffold materials are labeled with ultrasmall superparamagentic iron oxide (USPIO) nanoparticles, enabling their visualization and monitoring using magnetic resonance imaging. USPIO nanoparticles possessing different surface functionalities are incorporated either physically or chemically into the scaffolds. Labeled scaffolds are shown to be highly biocompatible and suitable for tissue engineering applications. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Bozkurt A.,RWTH Aachen | Lassner F.,RWTH Aachen | O'Dey D.,RWTH Aachen | Deumens R.,RWTH Aachen | And 15 more authors.
Biomaterials | Year: 2012

The use of bioengineered nerve guides as alternatives for autologous nerve transplantation (ANT) is a promising strategy for the repair of peripheral nerve defects. In the present investigation, we present a collagen-based micro-structured nerve guide (Perimaix) for the repair of 2 cm rat sciatic nerve defects. Perimaix is an open-porous biodegradable nerve guide containing continuous, longitudinally orientated channels for orientated nerve growth. The effects of these nerve guides on axon regeneration by six weeks after implantation have been compared with those of ANT. Investigation of the regenerated sciatic nerve indicated that Perimaix strongly supported directed axon regeneration. When seeded with cultivated rat Schwann cells (SC), the Perimaix nerve guide was found to be almost as supportive of axon regeneration as ANT. The use of SC from transgenic green-fluorescent-protein (GFP) rats allowed us to detect the viability of donor SC at 1 week and 6 weeks after transplantation. The GFP-positive SC were aligned in a columnar fashion within the longitudinally orientated micro-channels. This cellular arrangement was not only observed prior to implantation, but also at one week and 6 weeks after implantation. It may be concluded that Perimaix nerve guides hold great promise for the repair of peripheral nerve defects. © 2011 Elsevier Ltd.


Gucciardo L.,Catholic University of Leuven | Gucciardo L.,University Hospital Leuven | Ozog Y.,Catholic University of Leuven | Rusconi S.,University Hospital Leuven | And 4 more authors.
Journal of Pediatric Surgery | Year: 2014

Background Large congenital diaphragmatic hernia may require prosthetic correction. Acellular collagen matrices were introduced to avoid complications owing to the use of synthetic patches. We tested 3 different ACM for reconstruction of an abdominal wall defect in an animal model that mimics the fast growth during infancy.Methods Pelvisoft® (CR Bard, Covington, GA) and 2 investigational ACM were used for primary reconstruction of a full thickness abdominal wall defect. 3 months-old rats (n = 26) were allowed to survive for 90 days after implantation. Anatomical, tensiometric and histological analyses were performed. Based on good outcomes, we did the same with 1 month-old rats (n = 54). Unoperated rats were used for obtaining reference tensiometric values of selected native tissues.Results Major wound complications were exclusively observed in 1 month-old rats. All explants in both groups thinned significantly (p < 0.03) and had an elastic modulus increasing over time, far above that from native tissues at 90 days of life. Both investigational ACM induced a more vigorous foreign body reaction than Pelvisoft®.Conclusions The shift from 3 to 1 month-old rats was associated with wound complications. Pelvisoft® showed a better biocompatibility than the 2 investigational ACM. Passive biomechanical properties of all explants were still not comparable to that of native tissues. © 2014 Elsevier Inc. All rights reserved.


Seifarth V.,FH Aachen | Gossmann M.,FH Aachen | Janke H.P.,Radboud University Nijmegen | Grosse J.O.,RWTH Aachen | And 4 more authors.
Urologia Internationalis | Year: 2015

Regenerative medicine, tissue engineering and biomedical research give hope to many patients who need bio-implants. Tissue engineering applications have already been developed based on bioreactors. Physiological ureter implants, however, do not still function sufficiently, as they represent tubular hollow structures with very specific cellular structures and alignments consisting of several cell types. The aim of this study was to a develop a new bioreactor system based on seamless, collagenous, tubular OPTIMAIX 3D prototype sponge as scaffold material for ex-vivo culturing of a tissue engineered ureter replacement for future urological applications. Particular emphasis was given to a great extent to mimic the physiological environment similar to the in vivo situation of a ureter. NIH-3T3 fibroblasts, C2C12, Urotsa and primary genitourinary tract cells were applied as co-cultures on the scaffold and the penetration of cells into the collagenous material was followed. By the end of this study, the bioreactor was functioning, physiological parameter as temperature and pH and the newly developed BIOREACTOR system is applicable to tubular scaffold materials with different lengths and diameters. The automatized incubation system worked reliably. The tubular OPTIMAIX 3D sponge was a suitable scaffold material for tissue engineering purposes and co-cultivation procedures. © 2015 S. Karger AG, Basel.


Boekema B.K.H.L.,Association of Dutch Burn Centres | Vlig M.,Association of Dutch Burn Centres | Olde Damink L.,Matricel GmbH | Middelkoop E.,Association of Dutch Burn Centres | And 5 more authors.
Journal of Materials Science: Materials in Medicine | Year: 2014

Collagen-elastin (CE) scaffolds are frequently used for dermal replacement in the treatment of full-thickness skin defects such as burn wounds. But little is known about the optimal pore size and level of cross-linking. Different formulations of dermal substitutes with unidirectional pores were tested in porcine full-thickness wounds in combination with autologous split skin mesh grafts (SSG). Effect on wound healing was evaluated both macro- and microscopically. CE scaffolds with a pore size of 80 or 100 μm resulted in good wound healing after one-stage grafting. Application of scaffolds with a larger average pore size (120 μm) resulted in more myofibroblasts and more foreign body giant cells (FBGC). Moderate crosslinking impaired wound healing as it resulted in more wound contraction, more FBGC and increased epidermal thickness compared to no cross-linking. In addition, take rate and redness were negatively affected compared to SSG only. Vascularization and the number of myofibroblasts were not affected by cross-linking. Surprisingly, stability of cross-linked scaffolds was not increased in the wound environment, in contrast to in vitro results. Cross-linking reduced the proliferation of fibroblasts in vitro, which might explain the reduced clinical outcome. The non-cross-linked CE substitute with unidirectional pores allowed one-stage grafting of SSG, resulting in good wound healing. In addition, only a very mild foreign body reaction was observed. Cross-linking of CE scaffolds negatively affected wound healing on several important parameters. The optimal non-cross-linked CE substitute is a promising candidate for future clinical evaluation. © 2013 Springer Science+Business Media New York.


PubMed | University Hospital Leuven, Catholic University of Leuven and Matricel GmbH
Type: Journal Article | Journal: Journal of pediatric surgery | Year: 2014

Large congenital diaphragmatic hernia may require prosthetic correction. Acellular collagen matrices were introduced to avoid complications owing to the use of synthetic patches. We tested 3 different ACM for reconstruction of an abdominal wall defect in an animal model that mimics the fast growth during infancy.Pelvisoft (CR Bard, Covington, GA) and 2 investigational ACM were used for primary reconstruction of a full thickness abdominal wall defect. 3months-old rats (n=26) were allowed to survive for 90days after implantation. Anatomical, tensiometric and histological analyses were performed. Based on good outcomes, we did the same with 1month-old rats (n=54). Unoperated rats were used for obtaining reference tensiometric values of selected native tissues.Major wound complications were exclusively observed in 1month-old rats. All explants in both groups thinned significantly (p<0.03) and had an elastic modulus increasing over time, far above that from native tissues at 90days of life. Both investigational ACM induced a more vigorous foreign body reaction than Pelvisoft().The shift from 3 to 1month-old rats was associated with wound complications. Pelvisoft showed a better biocompatibility than the 2 investigational ACM. Passive biomechanical properties of all explants were still not comparable to that of native tissues.

Loading Matricel GmbH collaborators
Loading Matricel GmbH collaborators